Trials / Completed
CompletedNCT02071043
Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Gastric cancer with para-aortic lymph node (PAN) involvement is regarded as advanced disease, and only chemotherapy is recommended from the guidelines. In unresectable cases, neoadjuvant chemotherapy could prolong survival if conversion to resectability could be achieved.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine | Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3 |
| DRUG | Oxaliplatin | Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2013-01-01
- Completion
- 2013-01-01
- First posted
- 2014-02-25
- Last updated
- 2014-02-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02071043. Inclusion in this directory is not an endorsement.